Less than 15% of drugs that go through phase 1 trials end up passing phase 3. Drug discovery may be “easy” but we are not doing a very good job at it given the limited number of trials we can run. If AI can help rule out more of the molecules the hard part of the pharma business, running the trials, will become much more fruitful.